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Abstract
Purpose: Chemokine CXCL12 and its receptor CXCR4 are constitutively overexpressed in human
cancers. The CXCL12-CXCR4 signaling axis plays an important role in tumor progression and
metastasis, but also in treatment-induced recruitment of CXCR4-expressing cytotoxic immune cells.
Here, we aimed to demonstrate the feasibility of N-[11C]methyl-AMD3465 positron emission
tomography (PET) to monitor changes in CXCR4 density in tumors after single-fraction local
radiotherapy or in combination with immunization.
Procedure: TC-1 cells expressing human papillomavirus antigens E6 and E7 were inoculated
into the C57BL/6 mice subcutaneously. Two weeks after tumor cell inoculation, mice were
irradiated with a single-fraction 14-Gy dose of X-ray. One group of irradiated mice was
immunized with an alpha-viral vector vaccine, SFVeE6,7, and another group received daily
injections of the CXCR4 antagonist AMD3100 (3 mg/kg -intraperitoneal (i.p.)). Seven days after
irradiation, all animals underwent N-[11C]methyl-AMD3465 PET.
Results: PET imaging showed N-[11C]methyl-AMD3465 uptake in the tumor of single-fraction
irradiated mice was nearly 2.5-fold higher than in sham-irradiated tumors (1.07 ± 0.31 %ID/g vs.
0.42 ± 0.05 % ID/g, p G 0.01). The tumor uptake was further increased by 4-fold (1.73 ± 0.17 %
ID/g vs 0.42 ± 0.05 % ID/g, p G 0.01) in mice treated with single-fraction radiotherapy in
combination with SFVeE6,7 immunization. Administration of AMD3100 caused a 4.5-fold
reduction in the tracer uptake in the tumor of irradiated animals (0.24 ± 0.1 % ID/g, p G
0.001), suggesting that tracer uptake is indeed due to CXCR4-mediated chemotaxis.
Conclusion: This study demonstrates the feasibility of N-[11C]methyl-AMD3465 PET imaging to
monitor treatment-induced changes in the density of CXCR4 receptors in tumors and justifies further
evaluation of CXCR4 as a potential imaging biomarker for evaluation of anti-tumor therapies.
Key words: CXCR4 expression, Treatment monitoring, Cervical cancer, Immunization,
Radiotherapy, PET, Immune cell infiltration
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Introduction
CXCR4 is a seven-transmembrane G-protein coupled recep-
tor, which is overexpressed by stromal cells and tumor cells
in more than 20 different human cancers types [1]. CXCR4
is involved in various biological processes, including
immune cell trafficking, tumor growth, and metastasis [2–
7]. CXCR4 signaling is mediated by stromal derived factor-
1α (CXCL12) and leads to G-protein-mediated activation of
downstream signaling pathways via transcription factors that
promote cell proliferation, cell survival, angiogenesis,
invasion, and cell migration [8, 9].
Migration of cancer cells is directly dependent on the
interactions between cell surface molecules on the tumor
cells, like CXCR4, and the release of chemokines, like
CXCL12, by tissues that are targets for metastases. It is
believed that organs with high levels of CXCL12, such as
lymph nodes, lungs, liver, and bones, are the first destination
of metastatic tumor cells expressing CXCR4 receptors. This
hypothesis was supported by animal studies, showing that
CXCR4-positive tumor cells migrated from their primary
region to these CXCL12 secreting organs [10, 11]. The
CXCR4-CXCL12 signaling pathway, however, is not only
involved in the migration of cancer cells, but also in the
trafficking of stem cells and immune cells, such as CXCR4-
expressing hematopoietic stem cells, progenitor cells, pre-B
lymphocytes, and T lymphocytes [12, 13]. Increased
secretion of CXCL12 by the tumor, for example, as a result
of hypoxia or treatment, stimulates the infiltration of
CXCR4 expressing immune cells [14, 15].
High expression of CXCR4 by tumor cells has been
associated with treatment resistance [16, 17]. Recent data
indicate that standard chemotherapeutic agents and radio-
therapy can induce dynamic changes in the surface expres-
sion of CXCR4. This therapy-induced overexpression of
CXCR4 was suggested to be involved in acquired therapeu-
tic resistance [16, 17]. Moreover, mutations in the CXCR4
gene that lead to overexpression of CXCR4 receptors were
found to induce resistance towards conventional therapy [17,
18]. Inhibition of the CXCR4-CXCL12 axis, on the other
hand, can sensitize cancer cells to chemotherapy or
radiotherapy by inhibiting the interaction between the
CXCR4-expressing tumor cells and stromal cells, resulting
in decreased cancer cell protection by the CXCL12 releasing
stromal cells [19–21]. When radiotherapy or chemotherapy
of solid tumors was combined with the administration of a
CXCR4 antagonist such as AMD3100, a significant de-
crease in primary tumor volume and reduced metastatic
burden was observed [21–24]. The use of anti-CXCR4 drugs
can also potentiate the anti-tumor activity of several targeted
drugs, such as tyrosine kinase inhibitor or anti-PD-1 and
anti-CTLA4 antibodies [25–28].
Since the CXCR4-CXCL12 signaling pathway plays an
important role in oncogenesis, treatment-induced resistance and
immune cell trafficking, CXCR4 could be an interesting
biomarker to predict outcome and monitor treatment response.
We recently developed N-[11C]methyl-AMD3465 as a new
positron emission tomography (PET) tracer for imaging of
CXCR4 receptors [29, 30]. In vivo evaluation of this tracer
showed favorable receptor binding, biodistribution, and pharma-
cokinetics for imaging [29, 30]. The aim of the current study is to
demonstrate the feasibility of N-[11C]methyl-AMD3465 PET to
monitor treatment-induced changes in the density of CXCR4
receptors in the tumor. In particular, we investigated the effect of a
single-fraction radiotherapy, as an example of a conventional
treatment, and cancer immunization [32–34], as an example of an
experimental immunotherapy. In addition, tumor-bearing mice
were treatedwith theCXCR4 antagonist AMD3100 (Plerixafor®)
to inhibit the chemotaxis mediated by the CXCR4 receptor.
Materials and Methods
General
All chemicals and reagents were obtained from commer-
cial suppliers and used without further purification. The
drug AMD3100 octahydrochloride (AMD3100.8HCl;
Plerixafor®) was prepared as described in the literature
(Fig. 1) [29]. A stock solution of Plerixafor® was
prepared in phosphate-buffered saline (PBS), and the
pH of the solution was adjusted to neutral with 1 M
NaOH (Fig. 1). The radiotracer N-[11C]methyl-AMD3465
was prepared as previously described (Fig. 1) [30]. The
TC-1 cell line was created from C57BL/6 primary lung
epithelial cells by transfection with a retroviral vector
that expresses a fusion protein of the HPV16 early genes
E6 and E7 [32]. Cells were cultured as previously
described [33]. The production and quality control of
the Semliki Forest virus vector SFVeE6, 7 for immuni-
zation was performed as previously described [33].
Animal Model
All animal experiments were performed in the compli-
ance with the Dutch law on Animal experiments. The
Institutional Animal Care and Use Committee of the
University of Groningen (DEC6073E) approved the
protocol. Specified pathogen-free female C57BL/6 mice
between the age of 8 and 14 weeks were used (Harlan
CPB, The Netherlands). Mice were maintained at a 12 h/
12 h day/night regimen and fed standard laboratory
chow. Mice were subcutaneously inoculated in the neck
region with 2 × 104 TC-1 cells suspended in 0.05 ml
Hank’s balanced salt solution (Invitrogen, Paisley, UK).
The animals were randomly divided into four groups,
which received the following treatments: (1) sham-
irradiation (control, n = 5), (2) a local single-fraction of
14-Gy tumor irradiation (n = 6), (3) a single-fraction 14-
Gy tumor irradiation followed by immunization with
SFVeE6,7 (n = 6), and (4) the last group received a
single-fraction 14-Gy tumor irradiation followed by
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treatment with the CXCR4 antagonist AMD3100.8HCl (3
mg/kg i.p., n = 5). At the end of the study, animals were
euthanized, the tumor was harvested, and tumor weight
was measured before snap-freezing.
Treatments
Two weeks after tumor cell inoculation, mice were
anesthetized with isoflurane and placed in plastic con-
strainers to ensure immobilization for the localized
irradiation of the tumor. TC-1 tumors were subjected to
a local single-fraction 14-Gy dose of X-ray irradiation,
using an X-RAD 320 Biological Irradiator (Precision X-
Ray, North Branford, CT, USA). The X-ray delivery rate
was 1.64 Gy/min (1 Gy/min at 320 kV, 12.5 mA, 50 cm
SSD (HVL ≈ 4 mm Cu)). Sham-irradiated animals
underwent the same procedure, but the irradiation
equipment remained switched off. One day after irradi-
ation, one group (irradiated only) received a vehicle
injection (PBS), the second group of mice received a
single dose intramuscular injection of 5 × 106 SFVeE6,7
particles (irradiation + immunization group), and the last
group received daily intraperitoneal (i.p.) injections of
AMD3100.8HCl (3 mg/kg) until the end of the experi-
ment (6 days). The purpose of AMD3100 treatment in
this study is to block the CXCR4 dependent chemotaxis
by saturation of the CXCR4 receptors.
PET Acquisition
PET imaging experiments were performed 7 days after
irradiation. Mice were anaesthetized with isoflurane (5%
induction; 2% for maintenance) in medical air. Two
animals were placed in the prone position on a home-
made Perspex “bunk bed” in the PET camera (microPET
Focus 220; Siemens Medical Solution USA) with the
tumors in the field of view. Animals were injected with
20 ± 2 MBq of N-[11C]methyl-AMD3465 (0.45 ± 0.15
nmol) via the tail vein, and the acquisition of a 30-min
dynamic PET scan was started immediately. After the
emission scan was complete, a transmission scan of
900 s with a Co-57 point source was obtained for the
correction of attenuation and scatter by tissue.
Image Reconstruction
All the emission scans were normalized and corrected for
attenuation, scatter, and radioactive decay. Emission sino-
grams were iteratively reconstructed using an ordered subset
expectation maximization (OSEM) algorithm with 4 iter-
ations and 16 subsets. The final dataset consists of 6 frames
of 5 min, each containing 24 transverse slices with a slice
thickness of 0.8 mm and an in-plane 128 × 128 image matrix
with a pixel size of 1.1 mm. In order to have a better signal-
to-noise ratio and image quality, summed PET images were
used to draw volumes of interest (VOIs). These VOIs were
used for quantitative PET measurements of tracer uptake
using only the last frame (i.e., frame-6, 25–30 min). To
avoid partial volume effects, conservative VOIs were drawn
and the maximum tracer concentration in the VOI (in Bq/ml)
was quantified using Inveon standard software (Inveon,
Siemens, USA). The maximum tracer concentration in tissue
(Ct(max) - Bq/ml) was normalized to the injected activity
(Dinj – Bq) and multiplied by 100% to calculate the
percentage of the injected dose per gram tissue (%ID/g): it
was assumed that 1 ml of tissue corresponds to 1 g.
%ID
g




Immunohistochemistry (IHC) was performed as previously
described [29–31]. Tumors were harvested, snap-frozen in
liquid nitrogen, and stored in a freezer at − 80 °C until
required for further use. For each tumor, 3–5 sections were
prepared with a thickness of 5 μm. Then, the tissue was
fixed in acetone followed by washing with 2 % hydrogen
peroxide solution to block endogenous peroxidase activity.
To reduce non-specific binding, the sections were incubated
in 2.5% normal serum. Then, sections were incubated with
primary rabbit polyclonal anti-CXCR4 antibody (Abcam,
clone 2074; Cambridge, UK) at a dilution of 1:500 overnight
at 4 °C. Subsequently, the sections were incubated with the
secondary antibody, which was conjugated with horseradish
peroxidase (HRP), and the tertiary antibody, as was
described in the recommendations by the manufacturer
(Dako, Belgium). The slides were stained diaminobenzidine
Fig. 1. Structure of AMD3100, AMD3465, and N-[11C]methyl-AMD3465.
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(DAB), counterstained with hematoxylin and washed.
Control experiments, in which the addition of primary
antibody was eliminated, were performed to assess the
extent of non-specific staining. The slides were examined
under a microscope (Leica) at 10 different areas for each
sample and scored according to the staining (0, no; 1, weak;
2, moderate; and 3, strong staining). Based on the intensity
of staining, each area received a score and all areas were
summed to give a total score for each slide. To avoid any
error, an expert pathologist opinion was taken during
reading the slides. The slides with improper tumor sections
were excluded from the analysis; only slides with full tissues
were included in the study. For statistical analysis, we
included a minimum of three slides from each animal.
Statistical Analysis
All data are expressed as mean ± standard deviation (SD).
Statistical analyses by one-way ANOVA were performed
using GraphPad Prism 5. Probability (p) values lower than
0.05 were considered statistically significant.
Results
CXCR4 Imaging in the Tumor
Three weeks after tumor inoculation, all animals underwent
PET scanning. Figure 2 represents PET scans of the tracer
uptake in the TC-1 tumor after different treatments. The
tumors were clearly visualized and the uptake of tracer was
found to be homogenously distributed within most of the
tumors. Even in the sham-irradiated control group, the basal
expression of CXCR4 in the tumor could be detected.
The time-activity curves (TACs) of the tumor indicated
highest tumor uptake within 5 min after tracer injection
followed by washout (Fig. 3). The area under the curve
(AUC), calculated with the trapezoidal method, was approx-
imate 3.5 times higher for the irradiated group when
compared to the sham-irradiated control group (44 ± 2 %
ID/(g min) vs 14 ± 1 % ID/(g min), p G 0.01). For animals
that received irradiation in combination with immunization,
the AUC was even 5-fold higher than for sham-irradiated
controls (65 ± 1 % ID/(g min) vs. 14 ± 1 % ID/(g min), p G
0.01). In contrast, the AUC for the AMD3100-treated group
was 5.6-fold lower when compared to the irradiated group
(44 ± 2 % ID/(g min) vs. 8 ± 1 % ID/(g min), p G 0.01).
Moreover, the AUC of the irradiated animals treated with
AMD3100 was even 1.7-fold lower when compared to the
sham-irradiated control group (p G 0.05).
The tumors were most clearly visualized 25–30 min after
tracer injection. Figure 4 shows the quantitative N-
[11C]methyl-AMD3465 uptake in the tumor, as determined
from the 25–30 min frame 6 of the PET scan. Seven days
after irradiation with a single-fraction radiotherapy of 14 Gy,
the tracer uptake in the tumor was nearly 2.5-fold higher
than in the sham-irradiated group (1.07 ± 0.31 % ID (n = 6)/
g vs. 0.42 ± 0.05 % ID/g (n = 5), p G 0.01). When local
tumor irradiation was combined with immunization with a
single dose of SFVeE6,7 particles, tracer uptake in the tumor
was even further increased by approximately 70%, when
compared to mice that were treated with radiation alone
(1.73 ± 0.17 (n = 6), p G 0.01). In contrast, administration of
a daily dose of AMD3100 caused an almost 4.5-fold
reduction in tracer uptake in the tumor of irradiated animals
(0.24 ± 0.1 % ID/g (n = 5), p G 0.001). Moreover, tracer
uptake in the tumor of animals treated with AMD3100 was
significantly lower than uptake in tumors of sham-irradiated
animals (57%, p G 0.05).
Tracer Uptake in Major Organs
Apart from the tumor, organs such as liver, kidney, and heart
were also clearly visible in the PET images (Fig. 2). Tracer
uptake in the liver 25–30 min p.i. was nearly 15 times higher
than in the tumor. Tracer uptake in the liver of mice
receiving local tumor irradiation in combination with
immunization was approximately 20% higher (12.5 ± 2.5
%ID/g), when compared to the other groups (~ 10 % ID/g),
Fig. 2. N-[11C]methyl-AMD3465 PET images (5–30 min) of female C57BL/6 mice bearing a TC-1 tumor in the neck. a Tumor-
bearing mice were treated with a sham-irradiation, b single-fraction radiotherapy of 14 Gy on the tumor, c a single-fraction
radiotherapy followed by immunization with a single dose of 5 × 106 SFVeE6,7 particles, and d a single-dose irradiation
followed by daily administration of AMD3100 (3 mg/kg, i.p). e PET-CT fusion image showing a tumor bearing mice treated with
single-fraction radiotherapy along with immunization. The tumor was indicated by red dashed line. Lu lungs, Li liver, K kidney.
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but this difference was not statistically significant. Further-
more, the kidneys (66 ± 12 % ID/g) and bladder (71 ± 24 %
ID/g) were the organs with highest tracer uptake and
therefore clearly visible in the PET images (Table 1).
Kidneys and bladder uptake was not significantly different
among the groups, indicating that renal clearance of the
tracer was not significantly affected by the treatments.
Although heart and spleen were visible in the PET images,
quantification of tracer uptake in these organs was difficult,
due to spillover from liver. Tracer uptake in the brain was
low (0.5 % ID/g) and not significantly different among
groups. Furthermore, the tumor from all animals were
harvested at the end of the study to assess any treatment
effects, but no significant differences in the tumor weight
among the sham-irradiated, single-fraction radiotherapy, or
in combination with immunization or AMD3100-treated
groups were observed (0.86 ± 0.21 g vs 0.71 ± 0.13 g vs
0.65 ± 0.16g vs 0.74 ± 0.11 g, respectively, p 9 0.05). This
suggests that single-fraction radiotherapy alone or in
combination with single-dose immunization or AMD3100
treatment did not induce any effect on the tumor size or
tumor mass at the time of measurement.
Immunohistochemistry (IHC)
In order to support our PET results, the expression of
CXCR4 receptors in tumors was examined ex vivo. Immu-
nohistochemistry showed CXCR4 receptor expression in the
tumor in all groups. The intensity of staining was scored
semi-quantitatively [29–31], using a 4-point scale (0, no; 1,
weak; 2, moderate; and 3, strong staining). All tumors
showed relatively weak to moderate staining throughout the
tumor. When compared to the sham-irradiated control group,
the mice treated with single-fraction radiotherapy alone
showed a strong staining (15 ± 2 vs 32 ± 3, p G 0.01). The
staining intensity further increased in the group of mice
treated with the combination of single-fraction irradiation
and immunization (56 ± 4, p G 0.001). Mice treated with
single-fraction 14-Gy irradiation and AMD3100 showed
moderate staining which was not statistically different from
the staining intensity in sham-irradiated mice (23 ± 6 vs 15 ±
2, p = 0.09) (Fig. 5).
Fig. 3. PET-derived time activity curves of N-[11C]methyl-AMD3465 (5–30 min) of the tumor of sham-irradiated (control mice, n
= 5), a local single-fraction radiotherapy (14 Gy) irradiated mice (n = 6), single-fraction tumor irradiated in combination with
SFVeE6,7 immunized mice (n = 6) or in mice upon local 14-Gy tumor irradiation followed by daily AMD3100 treatment (n = 5, 3
mg/kg, i.p). All TACs were converted to percentage ID per gram (%ID/g).
Fig. 4. PET-derived tumor uptake of N-[11C]methyl-
AMD3465 in mice treated with sham-irradiation (n = 5), with
a local single-fraction radiotherapy (14 Gy, n = 6), or with
local tumor irradiation in combination with immunization with
a single dose of 5 × 106 SFVeE6,7 (n = 6), or with local tumor
irradiation in combination with daily AMD3100 treatment (n =
5, 3 mg/kg, i.p). Quantitive PET data was calculated from 25
to 30 min postinjection (frame 6). The tracer uptake was
expressed as maximum percentage injected dose per gram
tumor tissue (%ID/g). All bars represent the mean of the
maximum %ID/g, and error bars represent standard devia-
tions (SDs). Statistically significant differences are indicated
by *p G 0.05, **p G 0.01, and ***p G 0.001).
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Discussion
In the current study, we demonstrate the feasibility to
monitor the effect of radiation and cancer immunization on
CXCR4 receptor expression in the tumor using PET
imaging. The chemokine receptor CXCR4 is overexpressed
by many cancer types and associated with tumor progression
and the metastatic potential of the tumor. Consequently,
CXCR4 has been used as a drug target for adjuvant therapy.
In addition, CXCR4 receptors are expressed by tumor
infiltrating immune cells, where the CXCR4 receptors are
involved in chemotaxis. Because of the roles of CXCR4 in
tumor progression and immune cell trafficking, CXCR4
density in the tumor may be affected by treatment, either as a
result of altered CXCR4 expression by the tumor cells, or by
treatment-induced infiltration of immune cells.
In this study, we used TC-1 tumor-bearing mice to
investigate the effect of treatment on CXCR4 expression.
TC-1 tumors expressing the HPV E6 and E7 tumor antigens
represent HPV-infected tumors, such as cervical cancer. The
most common treatment for locally advanced cervical cancer
involves radiotherapy and/or chemotherapy. Despite suc-
cessful results obtained with these conventional treatments,
many patients still show intrinsic or acquired resistance to
these therapies [15–17]. In order to develop better alter-
natives for such patients, tumor vaccination is now under
investigation as a new therapeutic approach [32–35]. In this
study, we have investigated the feasibility of N-[11C]methyl-
AMD3465 PET imaging of CXCR4 receptors density in
tumor response to two way treatment strategies: conven-
tional radiotherapy alone and radiotherapy in combination
with experimental vaccination by immunization with
SFVeE6,7 viral replicon particles.
We hypothesized that CXCR4-mediated chemotaxis
could be involved in the immunological response to these
treatments, which would likely be accompanied by an
increase in CXCR4 density within the tumor. Here, we have
shown that local tumor irradiation indeed caused a signifi-
cant increase in the accumulation of the CXCR4 selective
probe N-[11C]methyl-AMD3465 in the tumor, indicating
that the CXCR4 density in the tumor is increased. The tracer
uptake was even further increased when local single-fraction
tumor irradiation was combined with immunization with a
Table 1. PET-derived N-[11C]methyl-AMD3465 tracer uptake in liver,
kidney, bladder, and brain after different treatments. The tracer uptake is
expressed as the maximum %ID/g. No statistically significant differences in
tracer uptake between groups were observed




Liver 9 ± 1 10 ± 2 12 ± 2 10 ± 2
Kidney 59 ± 12 62 ± 10 66 ± 12 60 ± 17
Bladder 69 ± 15 70 ± 18 71 ± 24 67 ± 26
Brain 0.5 ± 0.2 0.6 ± 0.1 0.7 ± 0.3 0.5 ± 0.2
Fig. 5. Immunohistochemistry of CXCR4 expression in TC-1 tumor sections. CXCR4 expression was monitored after different
treatments: a sham-irradiated (n = 5). b A local single-fraction 14-Gy radiotherapy (n = 6). c A single-fraction 14-Gy dose of
local tumor irradiation followed by immunization with a single dose of 5 × 106 SFVeE6,7 viral particles (n = 6). d A single 14-Gy
dose of local tumor radiation combined with daily AMD3100 (3 mg/kg, i.p.) treatment (n = 5). e CXCR4-negative staining without
primary antibody (negative control) and f H&E staining of the TC-1 tumor morphology. The brown staining represents the
CXCR4 expression on tumor cells and stromal cells. All the images were acquired at × 10 magnification and × 20 in the small
box. The red arrow indicates the tumor cell, and black arrow indicates the stromal cells.
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single dose of SFVeE6,7. This increase in CXCR4 density in
the tumor could be due to treatment-induced increase in the
secretion of CXCL12 by stromal cells. This may induce
overexpression of CXCR4 by tumor cells that attempt to
avoid apoptosis. Alternatively, radiotherapy-induced hyp-
oxia induces the production of hypoxia-inducible factor-1α,
which in turn stimulates the secretion of CXCL12. The
enhanced CXCL12 secretion by the hypoxic tumor may lead
to the recruitment of CXCR4 expressing bone marrow
derived immune cells in order to restore the vasculature of
the tumor after radiotherapy [14, 17, 36]. Furthermore,
tumor irradiation might have resulted in increased recruit-
ment of CXCR4-positive T lymphocytes at the tumor site as
a result of the acute immune response to treatment-induced
cell damage [37, 38]. In previous studies, we have shown
ex vivo that local tumor irradiation indeed resulted in a
strong increase in infiltrating T lymphocytes, which was
further increased when radiotherapy was combined with
immunization [33]. This increased influx of T-cells was
accompanied by an up-regulation of chemokines and their
receptors [33], which is in agreement with the result of the
present study. In a previous study, we also monitored the
effect of single-fraction 14-Gy local tumor irradiation in
combination with SFVeE6,7 immunization and irradiation
alone on the tumor infiltration of immune cells using
[18F]FB-IL2 PET [39]. A synergistic effect of treatment on
infiltrating tumor T-cells was seen, resulting in a 10-fold and
30-fold increase in tracer uptake in the tumor treated with
single-fraction local irradiation alone or in combination with
immunization, respectively. This may be the result of
CXCR4 expressing mediated T-cell influx or CXCR4-
mediated chemotaxis.
In this study, we also included a group of mice that
received single-fraction tumor irradiation, followed by daily
administration of the CXCR4-selective antagonist
AMD3100. As a result, treatment with the CXCR4 antag-
onist caused a strong reduction in the tumor uptake of N-
[11C]methyl-AMD3465 in irradiated mice. Administration of
AMD3100 likely has (at least partly) saturated the binding
sites of the CXCR4 receptors on tumor cells, stromal cells,
and immune cells, thus preventing specific binding of N-
[11C]methyl-AMD3465 to the receptor. In addition, inhibi-
tion of CXCR4-mediated chemotaxis by the antagonist
AMD3100 could have resulted in a reduction in the
radiation-induced infiltration of CXCR4-expressing immune
cells into the tumor. In fact, our previous study, [18F]FB-IL2
PET showed that the increase in T-cells induced by
radiotherapy/immunization could be partially prevented by
treatment with the CXCR4 receptor antagonist [39]. Thus,
the reduction in N-[11C]methyl-AMD3465 uptake in the
tumor after treatment with AMD3100 observed in this study
is likely the result of a combination of saturation of the
CXCR4 receptors by the antagonist and a reduction in T-cell
infiltration by inhibition of CXCR4-mediated chemotaxis.
All these data suggest that N-[11C]methyl-AMD3465
could detect the changes in the expression of CXCR4
receptors after radiotherapy or combination of radiotherapy/
immunization. However, N-[11C]methyl-AMD3465 PET is
not suitable for detecting the expression CXCR4 in or near
organs involved in metabolism and excretion, like liver,
bladder, or kidneys, because of the high background uptake
of the tracer in these organs. Other tracer for CXCR4, such
as [68Ga] pentixafor, may provide better contrast images,
since this tracer is internalized, resulting in Ga-68 remaining
trapped inside the cell. Thus, this tracer would reflect
CXCR4 receptor turn-over and may be less suitable for
assessing CXCR4 expression. The selection of the tracer,
however, will usually mainly depend on availability of
radioisotopes rather than the desired imaging properties.
Still, our results warrant further translation of this imaging
method to the studies in patients. An interesting application
could be to use repetitive PET imaging with N-[11C]methyl-
AMD3465 to investigate why some solid tumors become
resistant after radio- or chemotherapy. This would provide
information on the dynamic changes in receptors expression
and thus the role of CXCR4 mediated chemotaxis in the
development of therapy-induced resistance. Furthermore, the
application of a combination of two different tracers, for
example N-[11C]methyl-AMD3465 and [18F]FB-IL2, could
be of interest, as it would allow simultaneous investigation
of different aspects of the immune response to treatment,
such as chemotaxis and T-cell activation. This information
could give a more comprehensive insight in the activation
and infil trat ion of immune cells in the tumor
microenvironment.
Conclusion
Taken together, the results from this study have demon-
strated that monitoring of treatment-induced changes in
CXCR4 receptor density in the tumor by N-[11C]methyl-
AMD3465 PET is feasible. PET imaging showed that both
single-fraction radiotherapy and immunization can increase
the N-[11C]methyl-AMD3465 tracer uptake in the TC-1
tumor model. This increases in CXCR4 density is due to
either increased expression of the receptors on tumor cells or
increased tumor infiltration of CXCR4 expressing immune
cells.
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